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The two most significant impediments to renal allograft survival are rejection and the direct
nephrotoxicity of the immunosuppressant drugs required to prevent it. Calcineurin inhibitors
(CNI), a mainstay of most immunosuppression regimens, are particularly nephrotoxic. Until
less toxic antirejection agents become available, the only option is to optimize our use of
those at hand.
Aim
To determine whether intensive rabbit anti-thymocyte globulin (rATG) induction followed by
CNI withdrawal would individually or combined improve graft function and reduce graft chronic
histopathology–surrogates for graft and, therefore, patient survival. As previously reported, a
single large rATG dose over 24 hours was well-tolerated and associated with better renal
function, fewer infections, and improved patient survival. Here we report testing whether com-
plete CNI discontinuation would improve renal function and decrease graft pathology.
Methods
Between April 20, 2004 and 4-14-2009 we conducted a prospective, randomized, non-
blinded renal transplantation trial of two rATG dosing protocols (single dose, 6 mg/kg vs.
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divided doses, 1.5 mg/kg every other day x 4; target enrollment = 180). Subsequent mainte-
nance immunosuppression consisted of tacrolimus, a CNI, and sirolimus, a mammalian tar-
get of rapamycin inhibitor. We report here the outcome of converting patients after six
months either to minimized tacrolimus/sirolimus or mycophenolate mofetil/sirolimus. Pri-
mary endpoints were graft function and chronic histopathology from protocol kidney biop-
sies at 12 and 24 months
Results
CNI withdrawal (on-treatment analysis) associated with better graft function (p <0.001) and
lower chronic histopathology composite scores in protocol biopsies at 12 (p = 0.003) and 24
(p = 0.013) months, without affecting patient (p = 0.81) or graft (p = 0.93) survival, or rejec-
tion rate (p = 0.17).
Conclusion
CNI (tacrolimus) withdrawal at six months may provide a strategy for decreased nephrotoxi-





Modern transplantation was made possible by anti-rejection therapy that combined steroids
with a calcineurin inhibitor (CNI), the class of drugs that includes cyclosporine and tacrolimus
(tac). Unfortunately, while largely effective at preventing rejection, these agents also include
toxic side effects ranging from pernicious steroid mediated metabolic disturbances to direct
CNI nephrotoxicity that contributes to a rate of graft survival that is unacceptable, little better
than 50% after ten years.
In clinical trials, CNIs have been minimized, withdrawn, or avoided in hope of reducing
graft dysfunction and failure, and possibly cardiac dysfunction, but after prolonged CNI use
renal function doesn’t necessarily improve with CNI withdrawal [1–16]. Early replacement of
CNI with sirolimus (srl), a mammalian target of rapamycin inhibitor (mTORi, another class of
immunosuppressant) may improve renal function [17], but in patients who have progressed to
poor function, replacing CNI with sirolimus can result in severe proteinuria and graft failure,
suggesting that early discontinuation or minimization of CNI is required to realize significant
benefit [18].
To decrease the risk of rejection or donor-specific antibody development when CNIs are
minimized early, lymphocyte depletion with rabbit anti-thymocyte globulin (rATG) can be
used at transplantation to induce profound immunosuppression [19–28]. Since 1999, we have
used induction with rATG to enable early steroid withdrawal (ESW) and minimized mainte-
nance with combined low-dose tacrolimus and sirolimus [29–32]. Sirolimus brings with it sig-
nificant clinical challenges (e.g., poor wound healing, delayed graft function, hyperglycemia,
and proteinuria) [33–38], but its antineoplastic properties are beneficial [39], and the power-
fully immunosuppressive sirolimus/tacrolimus combination lowers the risk of rejection after
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ESW [40,41]. Adverse sirolimus effects can be minimized or avoided by gradual introduction
without dose loading; we delay sirolimus for up to six weeks in patients with obesity or poor
early renal function [33].
Although historically higher levels of combined tacrolimus/sirolimus have shown reduced
graft survival [42], by 2004 our blood-level targets for tacrolimus and sirolimus were 6–8 and
8–12 ng/ml, achievable after lymphocyte depletion with rATG induction (1.5 mg/kg on four
alternate days), which facilitates both minimizing and delaying introduction of these mainte-
nance agents. Steroids were administered only during rATG infusion at a total exposure12
mg/kg (maximum1.2 grams). We also collected protocol biopsies to enable early detection
and treatment of subclinical pathology [43,44]. With this approach, patient and graft survival
equaled outcomes with conventional triple-maintenance therapy (tacrolimus blood level, 8–12
ng/ml; mycophenolate mofetil (MMF), 1 g twice a day; prednisone, 5–20 mg each day)
[2,41,45–47]. However, our group and others observed no improvement in renal function.
We hypothesized that more intensive rATG induction could improve renal function by
reducing reperfusion injury and safely enabling further mTORi and CNI reduction, or even
CNI withdrawal [48–51]. Between 4-20-2004 and 4-14-2009 we conducted a 2x2 factorial trial
sequentially comparing single-dose vs. divided-dose rATG induction protocols, and, after six
months, aggressive CNI/mTORi minimization vs. delayed CNI withdrawal and replacement
with MMF [52]. The 2x2 factorial trial design, although uncommon in transplantation, can
address multiple hypotheses much more efficiently with less cost, shorter time frame, and
fewer patients [53,54]. In addition, this trial design allows detection of synergistic effects
between two treatments.
The primary endpoints of the trial were renal function and chronic graft histopathology.
We previously reported that single-dose rATG induction produces better patient survival and
graft function with fewer infections. The results reported below show, for the first time, the
effects of CNI minimization vs. withdrawal on renal function and chronic histopathology in a
prospective randomized trial with ESW.
Materials and Methods
Ethics Statement and CONSORT Accounting of Trial
Between 4-20-2004 and 4-14-2009 at the University of Nebraska Medical Center 180 recipients
of renal transplants were enrolled and allocated equally into a single center, prospective, ran-
domized, unblinded 2x2 factorial trial of rATG induction and CNI minimization vs. CNI with-
drawal. This study was conducted in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines and was approved by the University of Nebraska Institutional
Review Board (IRB # 286–03) and registered at ClinicalTrials.gov (#NCT00556933; https://
clinicaltrials.gov/ct2/show/NCT00556933). All patients provided written informed consent.
The de-identified trial data analyzed for this report (S1 Dataset) and a CONSORT checklist (S1
CONSORT Checklist) are included in the Supporting Information.
Study Design, Randomization, and Endpoints, and Donor and Recipient
Demographics
Primary and selected previous renal transplant recipients (non-immunological causes of graft
loss) age>18 were eligible for study participation. Patients were excluded if>65 years, had a
panel reactive antibody (PRA) score>75%, were human leukocyte antigen (HLA) identical, or
required steroids. Primary endpoints were renal function by calculated glomerular filtration
rate (GFR) using the abbreviated Modification of Diet in Renal Disease formula (aMDRD),
Renal Transplantation without Calcineurin Inhibitor Immunosuppression
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and acute and chronic renal histopathology (based on Banff ‘05 criteria) [55,56]. A post hoc
analysis of graft inflammation, i IFTA (inflammation in areas of kidney interstitial fibrosis and
tubular atrophy) and i Total (inflammation throughout the transplanted kidney) was also per-
formed [25,57]. Secondary endpoints included patient survival, graft survival, biopsy-proven
rejection, and infectious and non-infectious complications. Details are contained in the Fig 1
legend and in previous publications [52,58]. The study protocol (S1 Protocol), the defining cri-
teria for complications (S1 Criteria) and the treatment protocol for rejection (S1 Treatment)
are presented in the online Supporting Information.
Power Analysis and Statistics
Using a General Linear Model of Repeated Measures, we estimated that 160 patients would
provide 80% power with a two-sided 0.05 alpha level to detect a relative 10% difference in cal-
culated GFR after CNI withdrawal during the first year. Enrollment was raised to 180 (+12.5%)
during the trial to guarantee sufficient patients undergoing CNI withdrawal.
We compared the effect on renal function (GFR) of CNI withdrawal vs. CNI minimization
using a General Linear Model of repeated measures. Banff chronic histopathology scores were
compared using Fisher’s Exact Test. Differences in frequencies of infections between groups
were tested by Chi-square. Rates of patient survival, graft survival, and rejection were estimated
by the Kaplan-Meier method and subjected to Cox proportional hazard analysis. Both donor
and recipient factors were analyzed by multivariate logistic regression for possible association
with superior renal function. Data are presented as means ± standard deviation unless other-
wise specified. PASS, SAS, and SPSS software were used for the power and statistical analyses.
Immune Suppression
All recipients received 6 mg/kg intravenous rATG (Genzyme Corporation, Cambridge, MA,
USA) beginning at transplantation, either a single infusion over 24 hours or four 1.5 mg/kg
infusions on alternate days. Except to treat rejection, steroids were administered only with
rATG. Treatment for instances of acute tubular necrosis (ATN) or delayed graft function
(DGF) was as previously described.
Initial maintenance immunosuppression consisted of sirolimus and tacrolimus. After a
screening protocol biopsy at approximately six months, patients randomized to CNI with-
drawal were assessed to determine if CNI could safely be replaced with MMF. Protocol biopsies
were also obtained at approximately 12 and 24 months.
Viral, Fungal, and Pneumocystis Prophylaxis
All recipients received oral valganciclovir and clotrimazole for 3 months after transplantation;
CMV− recipients with a CMV+ donor received valganciclovir 3 months longer. Patients
treated with rATG for rejection received a repeated course of the antiviral prophylaxis used at
induction. Pneumocystis prophylaxis was with trimethoprim-sulfamethoxazole or, if allergic to
sulfa, diamino-diphenyl sulfone (Dapsone) or aerosolized pentamidine diisethionate for 3
months after transplantation.
CMV and BK Viral Surveillance
In CMV− recipients transplanted with kidneys from CMV+ donors, blood viral DNA load was
checked at 2 weeks, and then monthly for 6 months after valganciclovir was discontinued.
Patients with significant leukopenia (white blood cells<2,000) were routinely screened for
CMV viremia or infection. All patients underwent urine screening for BK virus at months 1, 3,
Renal Transplantation without Calcineurin Inhibitor Immunosuppression
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Fig 1. CONSORT flow diagram of randomized 2x2 trial of rATG induction dosing and delayed CNI withdrawal [52]. The study statisticians provided
computer-generated randomized assignments in sequentially-numbered, sealed opaque envelopes opened after obtaining consent for trial participation.
Randomization included stratification by race (Caucasian/Asian vs. non-Caucasian/Asian), donor type (living vs. deceased), and whether listed for eventual
pancreas transplantation. Study patients were identified and enrolled by attending transplant physicians and study coordinators. The integrity of the
treatment arm assignments made by this system was monitored and confirmed by the study statisticians. Two patients not meeting enrollment criteria were
consented and randomized in error, but were identified before transplantation and removed from participation in the trial.
doi:10.1371/journal.pone.0139247.g001
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6, 9, and 12, and then annually for 5 years. If urine screening showed more than 9 million viral
DNA copies, blood was screened also. Patients with renal dysfunction and BK viremia under-
went renal biopsy; asymptomatic patients with BK viremia more than 2,000 plasma BK DNA
copies per milliliter also were biopsied. This threshold for significant BK viremia is higher than
that now used by the authors.
Calcineurin-inhibitor Withdrawal
Patients were precluded from CNI withdrawal by evidence of sirolimus intolerance or biopsy-
proven acute rejection (BPAR) in either a clinically-indicated or six-month protocol biopsy.
Twenty-four hours after initiation of MMF therapy (1 g BID), CNI dose was reduced by 50%.
Sirolimus dose was increased by 25–50%, then progressively adjusted to achieve the target level
of 8–12 ng/ml. CNI was discontinued when sirolimus level reached8 ng/ml.
Assessment of Renal Function
GFR was estimated with the aMDRD equation, using all blood draws that provided serum cre-
atinine measurements within the specified post-transplantation intervals [55,59,60]. GFR
between treatment groups was compared and analyzed using a repeated measures general lin-
ear model with maximum likelihood estimation, an approach sensitive to differences between
small groups in spite of large intra-patient variance over time. Ordinary least-squares regres-
sion was not employed because in the context of repeated measures it can fail to recognize sig-
nificant effects in the model due to faulty estimation of the covariance structure of the data
[61].
Assessment of Renal Histopathology
We report 12 and 24 month biopsy findings both separately and combined. The combined
biopsy score analysis includes a single result from each patient; the most recent biopsy result
was used for the 74 patients with biopsies at both times. A post hoc analysis of Banff graft
inflammation categories i IFTA and I Total was also performed.
Diagnosis and Treatment of Acute Rejection
Rejection was confirmed by ultrasound-guided biopsies (BPAR) graded according to Banff
1997 or 2005 criteria [56] and treated as described in S3 (Treatment of Acute Cellular Rejection
after Renal Transplantation).
Assessment of Complications and Infections
Transplant infectious disease specialists (A.K. and D.F.) assessed bacterial and viral infections
according to standard criteria.
Results
Trial Conduct
CONSORT Accounting and Demographics (Fig 1, Tables 1 and 2). A CONSORT
accounting of patients screened for enrollment is presented in Table 1 and flow of patients
through the trial is shown in Fig 1. Recipient and donor demographics are shown in Table 2.
Follow-up averaged 51.8 ± 15.1 months after transplantation and 45.8 ± 14.9 months after CNI
withdrawal. The trial was concluded when all patients had been followed for at least two years.
Renal Transplantation without Calcineurin Inhibitor Immunosuppression
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Total rATG Exposure and Therapeutic Drug Monitoring (Fig 2, Table 3). Total rATG
exposure (induction, extended rATG for ATN, and as treatment for rejection) between the
CNI minimization and withdrawal groups was not different. Respectively, mg/kg rATG were:
intent-to-treat, 6.3 ± 1.6 vs. 6.4 ± 1.8 (p = 0.86), and on-treatment, 6.6 ± 2.7 vs. 6.8 ± 2.8
(p = 0.67). Mean immunosuppressant trough levels of both tacrolimus and sirolimus declined
over time (in accordance with study design), both during the first six months (Fig 2), and fol-
lowing CNI minimization vs. withdrawal (Table 3). On-treatment blood levels tended to be at
or just above the target upper limit except for sirolimus among CNI-withdrawn patients, which
averaged in the middle of the target range.
Management of CNI Withdrawal. Sixty-six of 90 patients randomized to be withdrawn
(73%) met final criteria (Fig 1). An equal number of patients from each rATG induction group
underwent CNI withdrawal (single-dose rATG 32 vs. divided-dose rATG 33, p = 1.0). During
the first two years post-transplantation, 48 withdrawn patients (74%) remained CNI free. Four-
teen patients (22%) returned temporarily to CNI use for an average of 3.4 ± 1.1 months, typi-
cally to avoid sirolimus-impaired wound healing after elective surgery. Only three patients
(5%) permanently resumed CNI-based maintenance.
Steroid Exposure. Of the 178 patients in our trial, 38 (21%) required administration of
steroids during the post-transplantation follow-up. Of these, 19 (50%) required a short course
(<1month) of prednisone for low-grade rejection. Thirteen of the remaining 19 patients failed
this approach or had higher-grade rejection episodes, and were placed on chronic prednisone
therapy. Six patients required steroids for unrelated medical reasons (e.g., serum sickness). Of
these 19 patients, eleven were randomized to CNI withdrawal and eight to minimization
(p = 0.63). Four had undergone CNI withdrawal and one had undergone CNI/sirolimus mini-
mization before initiating chronic steroid therapy for rejection (p = 0.18).
No Synergistic interaction between rATG Induction and CNIWithdrawal. No syner-
gistic interaction was observed between single-dose vs. divided-dose rATG induction and later
Table 1. CONSORT Accounting of Patients Screened for Study Enrollment.
Potentially eligible patients 604
Not approached 51
Assessed for eligibility 553
Declined participation 44
Did not satisfy study criteria 329 (59%)
Enrolled 180
Reasons for Study Ineligibility
Age >65 years 11%
Requiring steroid therapy 9%
Other medical, social, financial, etc. issues 8%
Age <19 years 7%
History of hepatitis B or C 5%
PRA >75% 3%
Kidney/pancreas simultaneous transplantation 3%
Previous rATG treatment 3%
Previous “other” transplant 3%
History of CMV or BK virus positivity 2%
ABO incompatible or donor-specific antibody 2%
Cardiovascular or vascular issues 2%
Extended criteria donor or donation after cardiac death 1%
doi:10.1371/journal.pone.0139247.t001
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CNI withdrawal in multivariate logistic regression analysis of either renal function or chronic
graft histopathology (p>0.40). This validated our 2x2 factorial trial design and justified inde-
pendent analysis of the effects of CNI withdrawal.
Table 2. Recipient and Donor Demographics.
CNI Minimization vs. Withdrawal Minimization Withdrawal
# of starting patients 88 90
Censored prior to 6 months1 5 6
Not withdrawn due to:
rejection N/A3 5
refused or could not afford sirolimus N/A 4
PI discretion N/A 4
BK virus N/A 2
death N/A 1
polycystic liver disease N/A 1
intractable mouth ulcers N/A 1
myocardial infarction N/A 1
Censored for rejection 6 months 5 N/A
# patients on treatment 78 65
Recipient Demographics ITT n = 88 90
Age at transplantation (years) 46.5 ± 11.6 47.9 ± 12.1
BMI 28.2 ± 5.1 28.9 ± 5.5
BMI > 30 33 (38%) 37 (41%)
Males 59 (67%) 62 (69%)
Living donor (related/unrelated) 28 / 25 32 / 23
Deceased donor (DD) 35 (40%) 35 (39%)
DD cold ischemia (hours) 14.5 ± 6.3 14.5 ± 8.2
PRA (%) 0.8 ± 3.8 1.2 ± 7.0
Donor/Recipient height ratio (ITT) 0.98 ± 0.08 1.0 ± 0.07
Donor/Recipient height ratio (On-treatment) 0.98 ± 0.08 1.0 ± 0.07
Antigen mismatch 3.3 ± 1.9 3.5 ± 1.7
CNI withdrawn N/A 65 (72%)
Race (Non-Caucasian/Asian) 11 (13%) 10 (11%)
CMV serostatus (D+/R- or D+/R+) 54 (61%) 53 (59%)
Donor Demographics
Age at procurement (years) 42.6 ± 12.1 39.3 ± 13.1
Males 41 (47%) 37 (41%)
BMI 27.5 ± 4.9 27.7 ± 4.7
Final creatinine (mg/dl) 1.0 ± 0.5 1.0 ± 0.5
DD grade2 A 11 (13%) 9 (10%)
DD grade2 B 14 (16%) 12 (13%)
DD grade2 C 6 (7%) 8 (9%)
DD <18 years of age 4 (5%) 6 (7%)
1Reasons for censoring patients before six months were equally distributed and included withdrawal of consent, scheduled pancreas transplantation,
transfer of care, death.
2Nyberg deceased donor scoring algorithm [62].
3Not Applicable.
doi:10.1371/journal.pone.0139247.t002
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Fig 2. Immunosuppression induction regimens andmaintenance target blood levels.
doi:10.1371/journal.pone.0139247.g002
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Primary Endpoints
CNIWithdrawal Associates with Improved Renal Function (Fig 3). During the 30 months
following CNI withdrawal there was superior renal function among those withdrawn whether
analyzed as intent-to-treat (ITT) (p<0.01,) (Fig 3A) or on-treatment (OT) (p<0.001) (Fig 3B).
This benefit was most notable among living-donor kidney recipients (p<0.001; deceased donors,
p = 0.046; both on-treatment) (Fig 3C and 3D).
In a multivariate logistic regression analysis of CNI minimized (n = 76 ITT, 63 OT) vs. with-
drawn (n = 71 ITT, 58 OT) patients that included as variables donor type (p = 0.18), induction
group (p = 0.15), donor age (p = 0.69), Nyberg score, and CNI withdrawal, only CNI with-
drawal (p = 0.02 on-treatment, p = 0.09 intent-to-treat) and Nyberg score (deceased donors
only, p<0.001) associated with renal function improvement after withdrawal (or six months).
CNI Withdrawal Associates with Reduced Chronic Renal Histopathology (Figs 4 and
5). 217 protocol biopsies were obtained from 138 patients (78% of enrollment) at 12 (Fig 4A)
or 24 months (Fig 4B); 79 (57%) of these patients were biopsied at both times. For patients
biopsied at both times, the most recent biopsy was used for the 12/24 month composite analy-
sis (Fig 4C). For intent-to-treat analysis, 71 of 90 (79%) CNI-minimized and 67 of 88 (76%)
CNI-withdrawn patients were biopsied. For on-treatment analysis, 57 of 65 (88%) CNI-with-
drawn patients underwent protocol biopsy at either 12 or 24 months, or both. 67 of 83 (81%)
CNI-minimized patients underwent protocol biopsy at either or both 12 or 24 months. Five
patients in the CNI-minimization arm were censored from the analysis due to early rejection.
48% of on-treatment CNI-withdrawn patients and 50% of on-treatment CNI-minimized
patients were biopsied at 24 months.
There was significantly less chronic injury in the on-treatment CNI withdrawal group in the
composite scores, primarily due to less IFTA (ci and ct). CNI withdrawal associated with
numerically lower chronic histopathology scores in both the 12 and 24 month protocol biop-
sies except for cv at 24 months. Multivariate logistic regression analysis showed some measures
of donor organ quality associated with elevated Banff chronic histopathology scores; donor
type for categories ah (p = 0.04) and ci (p = 0.05), donor age for ah (p = 0.07) and deceased-
donor Nyberg score for ci (p = 0.01). Nyberg score also associated significantly with a chronic
injury composite of ah + ci + ct + i total (p = 0.01).
The early trend toward more i IFTA among CNI withdrawn patients at 12 months
(p = 0.10) (Fig 5A) was absent by 24 months (p = 0.81) (Fig 5B) and in the combined 12 and 24
month biopsies (p = 0.76) (Fig 5C). The combined biopsies also showed lower i Total scores
among the CNI-withdrawn group (p = 0.05) (Fig 5C).
Table 3. Targeted and Actual Blood Levels of tacrolimus and sirolimus (ng/ml).
CNI Minimized Group
Tacrolimus Sirolimus Tacrolimus + Sirolimus
Months Target Actual Target Actual Target Actual
7–12 2–4 5.0 ± 2.0 4–6 6.8 ± 1.6 8–10 11.0 ± 2.4
13–24 2–4 4.6 ± 2.3 4–6 6.6 ± 1.7 8–10 10.5 ± 2.2
CNI Withdrawn Group
Tacrolimus Sirolimus MMF Dose (g, PO, QD)
Months Target Actual Target Actual Actual
7–12 N/A N/A 8–12 10.5 ± 1.2 1.9 ± 0.3
13–24 N/A N/A 8–12 10.4 ± 1.4 1.9 ± 0.3
doi:10.1371/journal.pone.0139247.t003
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Secondary Endpoints
CNI Withdrawal Did Not Affect Patient and Graft Survival. For over six years after
transplantation there were no apparent differences in patient survival (Fig 6A) or death-cen-
sored graft survival (Fig 6B) between the CNI withdrawal and minimization groups.Eight
patients died during the course of study follow-up; causes of the five deaths in the CNI-mini-
mized group included MI (1), cancer (3), and sepsis (1). Patients in the CNI-withdrawn group
died of bacterial sepsis (1), pulmonary embolism (1), and an accidental drug overdose (1).
Deaths occurred at an average of 2.3 ± 1.4 years after transplantation, at patient ages 59.2 ± 2.9
years (CNI minimized) and 52.0 ± 11.7 years (CNI withdrawn).
Fig 3. Effect of CNI withdrawal on renal function. The impact of CNI withdrawal on GFR was detected both by intent-to-treat (for all donors, p <0.01) and
on-treatment analyses of deviation from a pre-withdrawal baseline GFR for each patient. Post-transplantation months 3–6 GFR values were averaged for
use as baselines for CNI-minimization patients; for CNI-withdrawn patients, the three months preceding actual withdrawal were used. To ensure a valid on-
treatment comparison of the effects of CNI withdrawal, five patients in the CNI-minimization arm were censored from the analysis due to early rejection (<6
months) because such patients were disqualified from withdrawal in the CNI-withdrawn group. Each time point is the average percentage change of three
months of GFR scores.
doi:10.1371/journal.pone.0139247.g003
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There were seven instances of death-censored graft loss during follow-up. Four grafts were
lost in the CNI-minimized group due to: humoral rejection/BK nephropathy (1), chronic/acute
rejection (2), and non-compliance (1). Three grafts were lost in the CNI-withdrawn group due
to: transplant glomerulopathy (1), chronic/acute rejection (1), and non-compliance (1).
CNI Withdrawal Did Not Increase Risk of Acute Rejection. Protocol biopsies at 12 and
24 months (Table 4) showed no significant differences in frequency or severity of rejection
between CNI groups. There was one finding of BK virus at 12 months in a CNI-minimized
Fig 4. Chronic Banff injury score distributions by on-treatment CNI withdrawal status. Protocol biopsies collected at approximately 12 and 24 months
were scored by a transplant renal pathologist blinded to treatment group assignment (author K.F.) for evidence of rejection, BK virus nephropathy, antibody-
mediated rejection, recurrent disease, inflammation, and Banff 2005 categories of chronic renal injury. Chronic injury categories were arteriolar hyaline
thickening (ah), allograft glomerulopathy (cg), interstitial fibrosis (ci), tubular atrophy (ct), and vascular fibrous intimal thickening (cv). A chronic injury
composite score for each group was also created from the five individual injury category scores. Severity scores within each category could be 0 (<5%; none
or minimal), 1 (>5%—<25%; mild), 2 (>25%—<50%, moderate), or 3 (>50%, severe). The composite scores shown are the total numbers of ah, cg, ci, ct, and
cv scores in each severity grade (0, 1, 2, or 3). The proportions of patients in each severity grade (0, 1, 2, and 3) for both the individual categories and the
composite were compared using Fisher’s exact test. Intent-to-treat (ITT) p-values are included in the figure.
doi:10.1371/journal.pone.0139247.g004
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patient and one at 24 months in a CNI-withdrawn patient. We found no evidence of grade 2 or
3 rejection, antibody-mediated rejection, or recurrent disease in any protocol biopsy.
In the intent-to-treat analysis beginning at CNI withdrawal (or six months for those not
randomized to CNI withdrawal), the risk of rejection for the CNI-withdrawn vs. minimized
group, whether or not associated with graft dysfunction, did not approach statistical signifi-
cance (p = 0.67 and 0.33, respectively). Because 28% of patients randomized were unable or
unwilling to undergo CNI withdrawal, we performed an on-treatment analysis of rejection
events after CNI withdrawal (or six months) (Fig 7A and 7B). There was a trend toward more
rejection after CNI withdrawal (p = 0.17; Fig 7A) which became more pronounced among
patients who also exhibited graft dysfunction (p = 0.10; Fig 7B). The majority of on-treatment
rejection events in the CNI withdrawal group (82%) occurred within six months of withdrawal,
compared with 29% in the CNI-minimized group during the same time (p = 0.049).
Multivariate logistic regression analysis of covariates likely to associate with rejection after
withdrawal (single-dose rATG induction, deceased donor, CIT, gender, age, and sirolimus lev-
els) showed an increased risk of rejection with increasing CIT (p = 0.05), and a trend with
younger recipient age (p = 0.09). Rejection was not significantly associated with deceased
donors (p = 0.15), single-dose rATG induction (p = 0.19), or average sirolimus levels after
withdrawal (p = 0.72).
Complications and Infections after CNI Withdrawal. There were no significant differ-
ences in rates of infectious or non-infectious complications between the CNI-withdrawn and
CNI-minimized groups in either the intent-to-treat or on-treatment analyses. However, among
the CNI-withdrawn, there were trends in the on-treatment analysis toward a greater frequency
of transplant wound hernias requiring repair and fewer instances of ureteral obstruction
(Table 5).
Fig 5. Post hoc on-treatment analysis of graft inflammation (i IFTA & i Total). Inflammation was scored both within areas of interstitial fibrosis and tubular
atrophy (i IFTA) and throughout the biopsy (i Total). Severity scores within each category could be 0 (<5%; none or minimal), 1 (>5%—<25%; mild), 2 (>25%
—<50%, moderate), or 3 (>50%, severe). The proportions of patients in each score category (0, 1, 2, and 3) were compared using Fisher’s exact test.
doi:10.1371/journal.pone.0139247.g005
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Combined Impact of Single-dose rATG Induction with CNIWithdrawal (post hoc anal-
ysis) (Fig 8). Superior renal function (p = 0.06) (Fig 8A) and significantly less chronic injury
in the composited Banff categories (p<0.001) (Fig 8B) was observed in patients who received
Fig 6. On-treatment patient and death-censored graft survival after CNI withdrawal. P-values for the intent-to-treat analyses are also shown.
doi:10.1371/journal.pone.0139247.g006
Table 4. Rejection in Protocol Biopsies.
Banff Rejection Grade
Time after Transplantation CNI Regimen Borderline/ Suspicious 1A 1B
12 ± 2 Months Minimized n = 69 (72%) 6 (9%) 1 (1.4%) 1 (1.4%)
12 ± 2 Months Withdrawn n = 63 (77%) 8 (13%) 5 (8%) 1 (1.6%)
24 ± 4 Months Minimized n = 46 (52%) 8 (17%) 1 (2.1%) 0
24 ± 4 Months Withdrawn n = 34 (52%) 5 (15%) 0 0
doi:10.1371/journal.pone.0139247.t004
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the combination of single-dose rATG and CNI withdrawal vs. divided-dose rATG with CNI
minimization.
Discussion
The trial presented here would be challenging to perform with a multi-center design (multiple
protocol biopsies, maintenance of immunosuppression agent blood levels within narrow
ranges, etc.). Although multi-center trials are the gold standard, a single-center study offers
more consistent long-term follow-up and tighter control over multiple parameters, thus
enabling the implementation of a complex protocol. Our single-center trial benefited from
long-term patient oversight according to standardized written protocols and from the 2x2
design, which efficiently and cost-effectively allowed testing two interventions.
Fig 7. Rejection after CNI withdrawal.On-treatment Kaplan-Meier analyses and log-rank tests (CNI minimized, n = 77; withdrawn, n = 64); intent-to-treat
(ITT) p-values are included in the figures. (A) All biopsy findings of rejectionGrade 1A. The majority of rejection episodes after six months were low-grade
Banff 1A: CNI minimized, 73% (4/7); CNI withdrawn, 70% (7/10). The number of higher-grade rejection episodes was similar between the two groups: CNI
minimized, 27% (3-IB); CNI withdrawn, 30% (2-IB, 1-IIA). (B) RejectionGrade 1A accompanied by clinically elevated serum creatinine (>30% above
baseline). Only 18% of all rejection events in the CNI-minimized group were associated with an increase in serum creatinine. In contrast, 60% of rejection
events in the CNI-withdrawn group associated with elevated serum creatinine (p = 0.10).
doi:10.1371/journal.pone.0139247.g007
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Combining the two induction groups for analysis of the effects of CNI withdrawal vs. mini-
mization is appropriate when it can be shown there is not a significant interaction between the
induction treatment and the subsequent CNI maintenance regimen used. If a significant inter-
action between the induction and CNI maintenance regimens were observed, a four-group
analysis would have been appropriate, and indeed, is the only option allowed in reporting our
trial outcomes at clinicaltrials.gov. However, the interaction of rATG induction regimen and
CNI withdrawal was not statistically significant, thereby qualifying induction and withdrawal
for analyzing and reporting separately.
We have previously shown that single-dose rATG induction has a reduced complication
profile with superior long-term graft function in recipients of deceased donors after ESW and
CNI minimization [52,58]. Although not powered specifically to evaluate patient survival and
infection rates, use of single-dose rATG resulted in fewer infectious complications and
improved patient survival. The difference in patient survival was unexpected, but divided-dose
rATG associated with more severe and prolonged CD4 leukopenia, which correlated with mul-
tiple and more severe infections. Cox proportional hazard modeling showed that an increased
hazard of mortality significantly associated with divided-dose rATG, lower lymphocyte count,
serious infection, and deceased donors. Mortality was increased 27-fold among patients with
all four conditions [52].
The results reported here show, for the first time, that CNI withdrawal (vs. CNI/sirolimus
minimization) in a steroid-free environment improves renal function and reduces chronic allo-
graft injury without significant difference in patient or death-censored graft survival. As men-
tioned above, the trial outcomes are reported at the clinicaltrials.gov website as a comparison
Table 5. Complications and Infections.
Intent-to-treat On-treatment
Complications CNI Minimized CNI Withdrawn p-value CNI Withdrawn p-value
n = 88 90 65
rATG reaction 3 (3.4%) 6 (6.7%) 0.5 2 (5%) 0.70
ATN/DGF 4 (4.5%) 8 (8.9%) 0.37 6 (9%) 0.32
Myocardial infarction 1 (1.1%) 2 (2.2%) 1.0 1 (2%) 1.0
Cardiac arrhythmia 0 (0%) 2 (2.2%) 0.50 2 (3%) 0.18
Serum sickness 1 (1.1%) 2 (2.2%) 1.0 2 (3%) 0.57
Lymphocele requiring drainage 4 (4.5%) 6 (6.7%) 0.75 5 (8%) 0.50
Wound complications 2 (2.3%) 3 (3.3%) 1.0 2 (3%) 1.0
Transplant wound hernia requiring repair 7 (8.0%) 13 (14.4%) 0.24 11 (17%) 0.12
Ureteral obstruction 5 (5.7%) 2 (2.2%) 0.28 0 (0%) 0.07
Cancer 4 (4.5%) 5 (5.6%) 1.0 3 (5%) 1.0
Infections CNI Minimized CNI Withdrawn p-value CNI Withdrawn p-value
n = 88 90 – 64 –
Urinary tract infection 17 18 1.0 13 1.0
Bacterial pneumonia 5 3 0.50 1 0.40
Bacteremia 7 5 0.56 4 0.76
Fungal 1 2 1.0 1 1.0
CMV infection (disease, viremia, syndrome) 3 6 0.50 3 0.70
BK nephropathy 3 3 1.0 1 0.64
PTLD 3 0 0.12 0 0.26
Total infections 39 37 0.76 23 0.32
doi:10.1371/journal.pone.0139247.t005
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of four (instead of two) groups, where even these reduced group sizes show a significant
chronic renal histopathology benefit to single-dose rATG induction followed by CNI with-
drawal (p = 0.0004).
The analysis of the repeated measures/longitudinal data in this study was carried out with
linear mixed models for longitudinal data. These models use maximum likelihood estimation
in which all available data, not just complete cases, are used in the analysis [61]. With the
advent of powerful desktop computers and more sophisticated statistical software there is no
Fig 8. Combined impact of single-dose rATG induction with CNI withdrawal.On-treatment comparison of best and worst treatment combinations
(single-dose rATG with delayed CNI withdrawal vs. divided-dose rATG with delayed CNI minimization). (A) Renal function analyzed as in Fig 3. (B) Chronic
Banff renal graft histopathology as in Fig 4.
doi:10.1371/journal.pone.0139247.g008
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need to compromise data by imputing missing values, and data need not be collected only at
rigidly pre-specified time points. Clinical research need not be restrained by the computational
limitations of the past. In this trial we benefitted greatly by being easily able to model for differ-
ent co-factors, e.g., induction regimen, withdrawal status, CNI levels, sirolimus levels, donor
type, donor quality, age, race, gender, etc. With this approach we were able to show that what
associated with the primary endpoints (renal function and chronic histopathology composite
scores after CNI withdrawal) was CNI withdrawal status.
Overall, the safety of CNI withdrawal and minimization appeared similar, with no differ-
ences in rates of infectious complications or malignancies. Among the CNI-withdrawal group
in the on-treatment analysis, there was a suggestion of an increased rate of transplant wound
hernia repair and fewer instances of ureteral obstruction, probably related, respectively, to
increased sirolimus exposure and the exclusion from CNI withdrawal of patients with early
ureteral complications.
Prospectively randomized multi-center trials addressing the possible benefit of CNI with-
drawal have reported frequent adverse sirolimus effects and sirolimus discontinuation, likely
due to high target levels [63]. In contrast, our trial’s comparator arm minimized CNI and siroli-
mus after ESW. We use low-dose sirolimus without loading; only 5%-10% of our patients dis-
continue sirolimus because of complications, compared to up to 32% in studies targeting
higher levels [33,38].
As with our study, discontinuing CNIs in the Spare-the-Nephron trial associated with
improved renal function (at 12 months) without increased BPAR or graft failure [64]. A direct
comparison is difficult, as neither induction regimen nor steroid maintenance were specified in
the trial protocol. In contrast to our study, renal function was not different at 24 months, how-
ever at that point only half of their patients were on-treatment. An on-treatment analysis was
not reported.
Lebranchu et al, using non-lytic induction in a multi-center trial, sequentially withdrew
CNIs (three months) and steroids (eight months) [18,65]. At 10 months, their BPAR rates
were 17% (sirolimus+MMF) and 8% (CSA+MMF). In our on-treatment analysis at 12 months,
rejection rates were 6% (CNI withdrawn) and 3% (CNI minimized) (p = 0.34). The lower rates
of BPAR in our trial are likely due to our use of rATG induction along with steroid withdrawal
within seven days [66,67]. After 72 months, our cumulative rejection rates were 18% (CNI
withdrawn) and 10% (CNI minimized) (p = 0.17). Comparing these two studies suggests that
the risk of rejection in association with CNI withdrawal can be minimized with the use of lytic
induction. In addition, there are benefits to single-dose rATG induction not realizable with
either divided-dose rATG or non-lytic induction [48,49,68,69].
In the BENEFIT belatacept registry trial, CNI avoidance (vs. maintenance) produced
approximately 6% higher GFR levels at three years [70,71]. We observed an improvement in
GFR of 4% at three years; the greater improvement in the BENEFIT trial likely reflects higher
CNI exposure in their control arm when the relative pharmaceutical potency of the CNI used
is accounted for (CSA ~150 ng/ml vs. our trial, ~5 ng/ml tacrolimus) [72]. The BENEFIT/EXT
phase III trial (extended-criteria donors) also showed better renal function with CNI avoidance
and maintenance with MMF and prednisone [73]. Belatacept appears to allow for both early
steroid withdrawal and CNI avoidance when used in combination with lytic induction [74,75].
In our trial, patients with higher Nyberg score donors showed no renal function improvement
after CNI withdrawal, suggesting that regimens avoiding both sirolimus and CNI may be better
for such patients.
Because protocol biopsies are typically not performed in multicenter trials, there are fewer
comparisons in this area. Protocol biopsies were performed at 12 months in the BENEFIT trial,
however, which showed a significantly lower prevalence and severity of chronic allograft
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nephropathy in association with CNI avoidance. Similarly, we found a significant reduction at
both 12 and 24 months in the Banff chronic allograft injury composite score and IFTA. Nanki-
vell reported rapid development of chronic allograft nephropathy in kidney/pancreas recipients
(>95% CAN-1 by year two) [7,76]. Despite a comparatively slower rate of chronic injury devel-
opment in our study, we still observed significantly less chronic histopathology among the
CNI-withdrawn patients, independent of induction regimen.
Among CNI-withdrawn patients there was a trend toward more inflammation associated
with IFTA at 12 months (p = 0.10), possibly associated with the trend toward increased rejec-
tion soon after withdrawal. However, this trend disappeared with subsequent biopsies. While
there was less total graft inflammation (i Total) in the CNI withdrawal group at both 12 and 24
months, the difference only became significant in the combined 12 and 24 month analysis (Fig
3B). Others have shown that i IFTA and i Total are predictors of reduced graft function and
long-term survival [25,57]. The decrease in chronic allograft injury plus stable/reduced inflam-
mation associated with CNI withdrawal suggests that the slight increased risk of low-grade
rejection is an acceptable trade-off, but underscores the value of protocol biopsy in the early
detection and amelioration of injury processes [9,43,77,78].
The combined results from our 2x2 trial support the notions that single-dose rATG induc-
tion improves renal function and safety and CNI withdrawal significantly improves long-term
renal function and reduces renal histopathology. Single-dose rATG induction followed by
delayed CNI withdrawal appears to have the greatest impact on renal function and chronic his-
topathology. We believe that with close graft monitoring after CNI withdrawal, and by return-
ing those with rejection to CNIs, there is unlikely to be an increased risk of graft loss.
The trial’s limitations include being a non-blinded single-center trial with limited racial diver-
sity, a predominance of living donors, and a high percentage of patients not undergoing CNI
withdrawal. 27% of patients randomized to CNI withdrawal were not able to be withdrawn (pri-
marily due to rejection), but patients were withdrawn in sufficient numbers to enable detection
of a significant effect on both renal function and chronic graft histopathology. As mentioned
above, this is likely due to the sensitivity resulting from using all available data in the General Lin-
ear Model used to analyze renal function. Although we must acknowledge the possibility of a
false-positive finding, the improved renal function after CNI withdrawal is corroborated by the
very highly significant reduction in chronic graft histopathology among those patients. To miti-
gate a possible impact on patient randomization resulting from not reaching the goal of CNI
withdrawal in every patient so randomized, we censored from the analysis five patients in the
CNI-minimized group due to early rejection (<6 months) because such patients were disquali-
fied from withdrawal in the CNI-withdrawn group. We also included both intent-to-treat and
on-treatment analyses as appropriate to aid in the interpretation of results.
This study suggests that the potential benefits to using maintenance immunotherapy with
sirolimus (e.g., reduced risk of cancer) are best going to be appreciated if CNI levels are run
very low or eliminated. Whether the improvement we observed in renal function after CNI
withdrawal will impact long-term graft survival remains uncertain, but the reduced composite
Banff injury score, less IFTA, and stable if not reduced total inflammation suggests that
improved graft survival is possible. Future trials are warranted to determine the possible impact
on long-term graft survival of CNI-free maintenance regimens.
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